



Healthcare News and Deals - June 19th, 2025

1. Samsung Electronics (KRX: 005930) Invests \$175M in Element Biosciences' Series E to Become Largest Shareholder

Proceeds will fund commercialization, global expansion, and product-roadmap advancement across genomic, multiomic, and clinical-research solutions. Samsung said the investment reflects confidence in Element's progress and aligns with its focus on precision medicine and life-sciences innovation. ([Link](#))

2. Riptide Ventures, OSF Ventures, and CU Healthcare Innovation Fund Among Backers of Icarus Medical's Oversubscribed \$7.2M Series A, Joined by Highpoint, MedTech Connect, Neovate, and BLU Venture Investors

Proceeds will support US commercialization, product development, manufacturing expansion, clinical validation, and hiring. The company develops bracing technologies like the Ascender and Adonis knee braces for osteoarthritis. Icarus recently made the Inc. 5000 list after 1,283% three-year growth. ([Link](#))

3. WellSpan Health and Royal Philips (NYSE: PHG) Launch 7-Year AI and Imaging Strategic Alliance Across 12 Pennsylvania Hospitals

The research component—described as Philips' first such agreement with a U.S. community health system—examines how AI and digital tools improve throughput, cost, and workflow efficiency, with WellSpan targeting recovery of more than 500,000 workforce hours annually. WellSpan and Philips Research will co-develop new products from Philips' R&D pipeline. ([Link](#))

4. Rylo (formerly Nagish) Raises \$85M from General Catalyst's Customer Value Fund and Canaan to Scale AI Communication Tools for Deaf and Hard-of-Hearing Users

New AI capabilities target workplace accessibility, speaker characteristics, sentiment analysis, and real-time fraud detection. Its 2025 Sign.mt acquisition produced Rylo Sign, an AI sign-language translation platform bridging signed and spoken languages, advancing accessibility for the 37.5 million U.S. adults reporting hearing difficulty. ([Link](#))

5. Abridge Lands Strategic Investment from Eli Lilly (NYSE: LLY) and NVIDIA (NASDAQ: NVDA) Partnership as AI Scribe Expands into Payer and Life-Sciences Workflows

Founded in 2018, Abridge works with 300+ health systems including Kaiser Permanente and Johns Hopkins. New clinical-decision-support partners include the American Diabetes

Association and Journal of Clinical Oncology. The AI also identifies clinical-trial candidates and, via AHIMA collaboration, aligns coding with fee-for-service and value-based reimbursement. ([Link](#))

6. Nano Dimension (NASDAQ: NNDM) Signs Term Sheet with Infinite Epigenetics in \$890M Deal to Form a Nasdaq-Listed AI-Powered Preventive Health and Diagnostics Company

Backed by subsidiaries TruDiagnostic and Tally Health and 120,000+ epigenetic samples, the combined company would trade under ticker "IEAI" with \$400M+ cash. Co-founder Brad Keywell is an original Tempus AI investor; research partners include Harvard, Yale, and Stanford. ([Link](#))

7. Caffeinated Capital Leads Neion Bio's Oversubscribed \$23M Series A, Joined by New Backers Digitalis Ventures, Ensemble VC, and Trust Ventures Plus Follow-On From Haystack and Basis Set Ventures

Neion Bio utilizes frontier genetic engineering to turn chicken eggs into medicine factories for the production of complex, glycosylated proteins. Proceeds will expand its pipeline across biosimilars, innovative medicines, reagents, and animal health. The round follows the company's March 2026 stealth emergence and first commercial pharmaceutical partnership. ([Link](#))

8. The Toy Foundation Funds Expansion of Miller Children's & Women's Hospital Sensory Program, Backing Therapeutic Care Across Cancer, Infusion, and Pediatric ICU Units

With this new grant, the hospital will expand the program into three high-need areas: the Nightengales' Infusion Center, the Jonathan Jaques Children's Cancer Institute, and the Pediatric Intensive Care Unit. Funding will also strengthen the hospital's ability to rapidly deploy sensory support during mass casualty incidents, adding mobile sensory stations, toys, and interactive equipment for personalized care. ([Link](#))

9. COUR Pharma Closes \$50M Series B Led by Lumira Ventures and Roche Venture Fund, with New Investor Sanofi (NASDAQ: SNY) and Pfizer Ventures (NYSE: PFE)

Existing backers Alpha Wave Ventures, Pfizer Ventures, Angelini Ventures, and the T1D Fund also participated. Proceeds will advance CNP-103, an investigational nanoparticle therapy currently in a Phase 2 trial for recently diagnosed type 1 diabetes patients ages 12-35. The therapy aims to reprogram the autoimmune response to preserve insulin-producing islet cells. ([Link](#))

Events:

1. July 8 - Reuters Digital Health 2026

Reuters Digital Health brings together subject matter leaders for candid case studies, collaborative roundtables, and panel discussions focused on moving AI from pilot to practice, supporting patients and clinicians with smarter tools, and proving the value of digital health.



Healthcare Development & Innovation Group



HDIG SEARCH



HDIG PARTNERS



HDIG FUNDS

